Tauopathies are classified according to whether tau deposits predominantly contain tau
isoforms with three or four repeats of the microtubule-binding domain. Those in which four …

Alzheimer's disease (AD) is the most common neurodegenerative disorder where the
accumulation of amyloid plaques and the formation of tau tangles are the prominent …

A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468)
evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive …

Tau immunotherapies have advanced from proof-of-concept studies to over a dozen clinical
trials for Alzheimer's disease (AD) and other tauopathies. Mechanistic studies in animal and …

Brain proteins function in their soluble, native conformation and cease to function when
transformed into insoluble aggregates, also known as amyloids. Biophysically, the soluble-to …

Tau-targeting antibody therapies: too late, wrong epitope or wrong target? | Nature
Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …

We read with interest the Article by Günter Höglinger and colleagues reporting the results of
a phase 2, randomised, placebo-controlled trial of tilavonemab for patients with progressive …

Physiological and pathological ageing (as exemplified by Alzheimer's disease, AD) are
characterized by a progressive decline that also includes cognition. How this decline can be …

The arrival of effective gene therapies for congenital neuromuscular disease is enormously
encouraging; however, it brings ethical challenges. In the past 5 years, many families of …

Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder for
which there are currently no disease-modifying therapies. The neuropathology of PSP is …